Background-Venous thromboembolism (VTE) is common following lung transplantation. Enoxaparin is an approved therapy for VTE and anti-factor Xa (AXAL) can be used to monitor enoxaparin activity. Some studies have demonstrated elevated AXALs are associated with an increased risk of hemorrhage. Having identified a high incidence of supratherapeutic AXALs in lung transplant recipients, we aimed to elucidate the relationship between enoxaparin dose and AXAL in this patient population.
versus the VORI group (0.89 per person-year)(IRR = .37, 95%CI 0.95-1.01, p= 0.037). However, fungal infection rates were similar: 0.41/person-year in the POSA group and 0.37/person-year in the VORI group (IRR = 1.11; 95%CI 0.32 -3.14, p= 0.805). Conclusion: Rates of fungal infection are low in patients who received POSA prophylaxis and are similar to those who received VORI. Interestingly, the rates of colonization are lower in those who received POSA prophylaxis. Though limited by sample size, taken in context with data from other organ transplant populations, our data suggests POSA may be a reasonable alternative to VORI.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.